Development of an encapsulated stem cell-based therapy for diabetes

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Introduction: Islet transplantation can treat the most severe cases of type 1 diabetes but it currently requires deceased donor pancreata as an islet source and chronic immunosuppression to prevent rejection and recurrence of autoimmunity. Stem cell-derived insulin-producing cells may address the shortage of organ donors, whereas cell encapsulation may reduce or eliminate the requirement for immunosuppression, minimizing the risks associated with the islet transplantation procedure, and potentially prolonging graft survival.Areas covered: This review focuses on the design principles for immunoisolation devices and on stem cell differentiation into insulin-producing cell products. The reader will gain understanding of the different types of immunoisolation devices and the key parameters that affect the outcome of the encapsulated graft. Progresses in stem cell differentiation towards mature endocrine islet cells, including the most recent clinical trials and the challenges associated with the application of immunoisolation devices designed for primary islets to stem-cell products, are also discussed.Expert opinion: Recent advancements in the field of stem cell-derived islet cell products and immunoisolation strategies hold great promise for type 1 diabetes. However, a combination product including both cells and an immunoisolation strategy still needs to be optimized and tested for safety and efficacy.

Original languageEnglish (US)
Pages (from-to)1321-1336
Number of pages16
JournalExpert Opinion on Biological Therapy
Volume15
Issue number9
DOIs
StatePublished - Sep 2 2015

Fingerprint

Medical problems
Cell- and Tissue-Based Therapy
Stem cells
Stem Cells
Islets of Langerhans Transplantation
Type 1 Diabetes Mellitus
Islets of Langerhans
Grafts
Equipment and Supplies
Immunosuppression
Cell Differentiation
Tissue Donors
Insulin
Transplantation (surgical)
Endocrine Cells
Expert Testimony
Graft Survival
Autoimmunity
Encapsulation
Pancreas

Keywords

  • Hydrogels
  • islet transplantation
  • macroencapsulation
  • microencapsulation
  • scaffold
  • vascular supply

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

Development of an encapsulated stem cell-based therapy for diabetes. / Tomei, Alice; Villa, Chiara; Ricordi, Camillo.

In: Expert Opinion on Biological Therapy, Vol. 15, No. 9, 02.09.2015, p. 1321-1336.

Research output: Contribution to journalArticle

@article{20cc2197b7704c4eb9484520487f3580,
title = "Development of an encapsulated stem cell-based therapy for diabetes",
abstract = "Introduction: Islet transplantation can treat the most severe cases of type 1 diabetes but it currently requires deceased donor pancreata as an islet source and chronic immunosuppression to prevent rejection and recurrence of autoimmunity. Stem cell-derived insulin-producing cells may address the shortage of organ donors, whereas cell encapsulation may reduce or eliminate the requirement for immunosuppression, minimizing the risks associated with the islet transplantation procedure, and potentially prolonging graft survival.Areas covered: This review focuses on the design principles for immunoisolation devices and on stem cell differentiation into insulin-producing cell products. The reader will gain understanding of the different types of immunoisolation devices and the key parameters that affect the outcome of the encapsulated graft. Progresses in stem cell differentiation towards mature endocrine islet cells, including the most recent clinical trials and the challenges associated with the application of immunoisolation devices designed for primary islets to stem-cell products, are also discussed.Expert opinion: Recent advancements in the field of stem cell-derived islet cell products and immunoisolation strategies hold great promise for type 1 diabetes. However, a combination product including both cells and an immunoisolation strategy still needs to be optimized and tested for safety and efficacy.",
keywords = "Hydrogels, islet transplantation, macroencapsulation, microencapsulation, scaffold, vascular supply",
author = "Alice Tomei and Chiara Villa and Camillo Ricordi",
year = "2015",
month = "9",
day = "2",
doi = "10.1517/14712598.2015.1055242",
language = "English (US)",
volume = "15",
pages = "1321--1336",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Development of an encapsulated stem cell-based therapy for diabetes

AU - Tomei, Alice

AU - Villa, Chiara

AU - Ricordi, Camillo

PY - 2015/9/2

Y1 - 2015/9/2

N2 - Introduction: Islet transplantation can treat the most severe cases of type 1 diabetes but it currently requires deceased donor pancreata as an islet source and chronic immunosuppression to prevent rejection and recurrence of autoimmunity. Stem cell-derived insulin-producing cells may address the shortage of organ donors, whereas cell encapsulation may reduce or eliminate the requirement for immunosuppression, minimizing the risks associated with the islet transplantation procedure, and potentially prolonging graft survival.Areas covered: This review focuses on the design principles for immunoisolation devices and on stem cell differentiation into insulin-producing cell products. The reader will gain understanding of the different types of immunoisolation devices and the key parameters that affect the outcome of the encapsulated graft. Progresses in stem cell differentiation towards mature endocrine islet cells, including the most recent clinical trials and the challenges associated with the application of immunoisolation devices designed for primary islets to stem-cell products, are also discussed.Expert opinion: Recent advancements in the field of stem cell-derived islet cell products and immunoisolation strategies hold great promise for type 1 diabetes. However, a combination product including both cells and an immunoisolation strategy still needs to be optimized and tested for safety and efficacy.

AB - Introduction: Islet transplantation can treat the most severe cases of type 1 diabetes but it currently requires deceased donor pancreata as an islet source and chronic immunosuppression to prevent rejection and recurrence of autoimmunity. Stem cell-derived insulin-producing cells may address the shortage of organ donors, whereas cell encapsulation may reduce or eliminate the requirement for immunosuppression, minimizing the risks associated with the islet transplantation procedure, and potentially prolonging graft survival.Areas covered: This review focuses on the design principles for immunoisolation devices and on stem cell differentiation into insulin-producing cell products. The reader will gain understanding of the different types of immunoisolation devices and the key parameters that affect the outcome of the encapsulated graft. Progresses in stem cell differentiation towards mature endocrine islet cells, including the most recent clinical trials and the challenges associated with the application of immunoisolation devices designed for primary islets to stem-cell products, are also discussed.Expert opinion: Recent advancements in the field of stem cell-derived islet cell products and immunoisolation strategies hold great promise for type 1 diabetes. However, a combination product including both cells and an immunoisolation strategy still needs to be optimized and tested for safety and efficacy.

KW - Hydrogels

KW - islet transplantation

KW - macroencapsulation

KW - microencapsulation

KW - scaffold

KW - vascular supply

UR - http://www.scopus.com/inward/record.url?scp=84938837429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938837429&partnerID=8YFLogxK

U2 - 10.1517/14712598.2015.1055242

DO - 10.1517/14712598.2015.1055242

M3 - Article

VL - 15

SP - 1321

EP - 1336

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 9

ER -